# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 31-40 of 2194 results.
An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)
Status: Completed
Last Changed: Apr 07, 2017
First Received: Dec 02, 2004
Disease(s): B-cell Lymphoma
Intervention(s): MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months
Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)
Status: Completed
Last Changed: Nov 04, 2014
First Received: Feb 12, 2010
Disease(s): B-cell Lymphomas
Intervention(s): Oxaliplatin, Prednisolone
Locations: Dong-A University Hospital, Busan, Korea, Republic of
Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma
Status: Recruiting
Last Changed: Jan 31, 2020
First Received: Jan 31, 2020
Disease(s): Large B-cell Lymphoma
Intervention(s): BZ019
Locations: Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin, China
Tianjin medical university cancer institute and hospital, Tianjin, China
Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)
Status: Active, not recruiting
Last Changed: Sep 19, 2019
First Received: Feb 12, 2014
Disease(s): Diffuse Large B-Cell Lymphoma
Intervention(s): Gemcitabine, Methylprednisolone, Rituximab, Cisplatin, Lenalidomide
Locations: Royal Marsden NHS Foundation Trust - London and Surrey, London, United Kingdom
Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)
Status: Terminated
Last Changed: Jan 27, 2017
First Received: Aug 24, 2015
Disease(s): Diffuse Large B-Cell Lymphoma
Intervention(s): Metformin, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, pegfilgrastim
Locations: Rush University Medical Center, Chicago, Illinois, United States
Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL)
Status: Not yet recruiting
Last Changed: Apr 21, 2020
First Received: Mar 09, 2020
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): molecular characterization
Locations: Irst Irccs, Meldola, FC, Italy
Ospedale S. Maria delle Croci RAVENNA, Ravenna, RA, Italy
Ospedale Infermi, Rimini, Italy
Multi-CAR-T Cells Targeting B Cell Lymphomas
Status: Recruiting
Last Changed: Jun 12, 2020
First Received: Jun 12, 2020
Disease(s): B Cell Lymphoma (BCL)
Intervention(s): 4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2
Locations: Shenzhen Children's Hospital, Shenzhen, Guangdong, China
Shenzhen Geno-Immune Medical Institute, Shenzhen, Guangdong, China
The Seventh Affilliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong, China
A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients
Status: Unknown status
Last Changed: Apr 11, 2017
First Received: Oct 26, 2016
Disease(s): B-Cell Lymphoma
Intervention(s): IBI301, Rituximab
Locations: Beijing cancer hospital, Beijing, Beijing, China
Peking University third hospital, Beijing, Beijing, China
The 307th Hospital of Military Medical Sciences, Beijing, Beijing, China
Harbin Medical University Cancer Hospital, Haerbin, Heilongjiang, China
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
... and 8 other locations.
Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Status: Not yet recruiting
Last Changed: Jan 31, 2019
First Received: Jan 31, 2019
Disease(s): Refractory B-Cell Lymphoma
Intervention(s): Anti-CD19 iCAR NK Cells
Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Status: Not yet recruiting
Last Changed: Jan 31, 2019
First Received: Jan 31, 2019
Disease(s): Refractory B-Cell Lymphoma
Intervention(s): Anti-CD19/CD22 CAR NK Cells